Teva's Innovation Engine Offsets Generics Slump, Leaving Analyst Shocked by Ajovy Surge on July 29, 2026 Ajovy analysts engine generics revenue generics slump innovation innovation pipeline innovation strategy Market Medical Specialities Migraine Disorders portfolio specialty brands strategic shift Teva valuation +
With ADA 2026 data in the books, analysts say Lilly is widening its lead in the obesity race on June 10, 2026 Adangme language analysts Eli Foundayo Lilly obesity Obesity Race:Type:Point in time:^Patient:Nominal retatrutide TRIUMPH TRIUMPH program Zepbound +
Aardvark Therapeutics Stock Plunges 54% Following Phase 3 Trial Pause on March 02, 2026 AARD gene Aardvark Therapeutics analysts ARD-101 BioNTech cardiac safety clinical development DualityBio Pauses Phase 3 trial Prader-Willi Syndrome therapeutic autologous dendritic cells +
Novo Execs Face Skeptical Analysts Amid Metsera Buyout Drama on November 05, 2025 acquisition analysts antitrust Buyout CEO Mike lawsuit Metsera Novo Nordisk Obesity Pfizer +
Nektar Declares Phase IIb Eczema Win for Rezpeg, but Analysts Remain Skeptical on June 25, 2025 analysts Clinical Trials Dermatitis, Atopic Dupixent EASI Eczema Lilly partnership Nektar Therapeutics Phase II B Trial Rezpeg Rezpegaldesleukin Score skepticism +
Patient suffers side effect in Cabaletta autoimmune CAR-T trial, but analysts unfazed on April 02, 2025 Adverse effects analysts aspects of adverse effects Autoimmune Diseases Cabaletta CAR-T therapy cell-associated neurotoxicity Lupus Erythematosus reSET (device) Systemic Systemic Scleroderma +
Unitys eye treatment fails to match Eylea, though analysts still see a path forward on March 24, 2025 analysts Eylea Macular edema due to diabetes mellitus match Eylea +